The Centers for Medicare & Medicaid Services (CMS) has begun a temporary Medicare GLP‑1 Bridge program that lets eligible Medicare Part D beneficiaries obtain certain GLP‑1 weight‑loss drugs for a $50 monthly copay.
Program details and covered drugs
The bridge, running from July 1 through Dec 31, 2027, offers three products: Foundayo, Wegovy (injections and tablets) and Zepbound KwikPen. Single‑dose vials and pens of Zepbound are excluded. Participants pay the $50 copay themselves; the cost does not count toward the Part D deductible or true out‑of‑pocket maximum, and low‑income subsidies do not apply.
Manufacturers will supply the drugs at a net price of $245 per monthly supply. The program operates outside the usual Part D benefit flow, so Part D sponsors bear no financial risk and do not need to opt‑in for beneficiaries.
Related: Nature’s beauty boosts mental wellbeing
Eligibility and prior‑authorization process
Eligibility is strict.
To qualify, a provider must submit a prior‑authorization request confirming the prescription is for excess‑body‑weight reduction and that the patient will follow a structured nutrition and activity plan. Beneficiaries must meet specific body‑mass‑index (BMI) thresholds linked to comorbidities. For example, a BMI of at least 35 qualifies on its own; a BMI of 30 is sufficient if the patient also has heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or higher. A BMI of 27 works when paired with prediabetes, prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease.
The request can be sent electronically or by fax, though CMS encourages electronic submission. Officials aim to process requests within 72 hours, and electronic filings should speed up the timeline.
Patients already covered for GLP‑1 drugs under Medicare for other FDA‑approved uses—such as type 2 diabetes, obstructive sleep apnea, or non‑cirrhotic metabolic dysfunction‑associated steatohepatitis—are not eligible for the bridge and must continue using their Part D plan.
Related: Why You Should Get a UPS
Humana will act as the central processor, using the Limited Income Newly Eligible Transition program’s infrastructure for prior‑authorization, claims adjudication and pharmacy payment.
CMS does not expect the bridge to affect Part D premiums because the costs are borne by the program, not the plans.
While the program is limited in scope, it gives the agency a way to collect data on utilization, adherence, and outcomes.
Broader context and financial implications
Medicare’s current coverage of GLP‑1 drugs is narrow, limited to FDA‑approved indications other than obesity. The bridge is part of a larger CMS effort that includes the BALANCE model, a separate innovation‑center initiative. Demand for GLP‑1 medications has risen sharply; a FAIR Health analysis reported that the share of adults with an overweight or obesity diagnosis receiving a GLP‑1 rose from 0.3 % in 2019 to 2.05 % in 2024, a relative increase of more than 586 %.
Related: Edwards agrees to $10 million FTC settlement
Cost estimates vary. A Health Affairs study projected that if anti‑obesity drugs were covered in 2025 and 5 % of newly eligible patients received one, Medicare Part D costs could climb by $3.1 billion annually; a 10 % uptake might add $6.1 billion. The Congressional Budget Office has separately forecasted that Medicare coverage of anti‑obesity meds could raise federal spending by about $35 billion from 2026 to 2034, with health‑related savings offsetting only a modest portion of those drug costs.
CMS Administrator Dr. Mehmet Oz described the bridge as a “practical pathway” that offers an “affordable, predictable price” for the American people. He noted that the program is about expanding access rather than shifting existing beneficiaries to a new payment model. Oz also called the effort a “psychology experiment” to see whether eligible individuals will actually use the medication consistently enough to generate health benefits.
As the program rolls out, officials say they have coordinated with pharmacies, prescribers, patient groups and physician societies to avoid rollout problems. They anticipate no premium impact for Part D plans and expect the bridge to operate smoothly.